How does Rybrevant (amivantamab) work?
Rybrevant is an antibody-based cancer medicine designed to block two targets on the surface of tumor cells: EGFR and MET. It binds to EGFR and MET, preventing signaling that helps tumors grow and spread, and it also promotes immune-mediated killing of cancer cells by recruiting immune effector functions.
Because it targets both pathways, Rybrevant is used to treat non-small cell lung cancer (NSCLC) cases where EGFR is a key driver and where MET-related resistance mechanisms can also be involved. [1]
What exactly does EGFR-blockade do?
EGFR (epidermal growth factor receptor) sends growth and survival signals inside the cell when it is activated. When Rybrevant binds to EGFR, it blocks those signals so the cancer cells receive fewer instructions to proliferate and survive.
In EGFR-driven cancers, continued EGFR signaling is one reason tumors keep growing, so interrupting that pathway is a direct anti-tumor mechanism. [1]
What does MET-blockade do, and why does it matter?
MET is another receptor that can drive tumor growth and survival. In some settings, cancers develop resistance or aggressive behavior through MET-related signaling (including MET gene alterations or pathway activation).
Rybrevant’s ability to bind MET helps shut down that alternate growth route, which can be important when EGFR alone is no longer enough to control the disease. [1]
Is Rybrevant just blocking receptors, or does it also engage the immune system?
Rybrevant’s mechanism includes both pathway inhibition and immune engagement. By binding to EGFR and MET on tumor cells, it can trigger immune-mediated responses that help eliminate cancer cells, not only by stopping signaling but also by recruiting the immune system to act against the tumor. [1]
What this means for resistance in EGFR-mutant NSCLC
In EGFR-mutant NSCLC, resistance can arise through additional signaling changes and bypass tracks. A two-target approach (EGFR plus MET) is intended to reduce tumor reliance on a single signaling axis, which can help address certain resistance mechanisms that involve MET. [1]
Source
[1] DrugPatentWatch.com: Rybrevant (amivantamab) mechanism and related drug information – https://www.drugpatentwatch.com/